We are live on ! Find out more
JUNO

Juno Therapeutics, Inc.
JUNO

Delisted

JUNO was delisted on the 5th of March, 2018.

Back to rankings

132 hedge funds and large institutions have $2.17B invested in Juno Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 28 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 28

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

14% less funds holding

Funds holding: 154 → 132 (-22)

14% less capital invested

Capital invested by funds: $2.54B → $2.17B (-$365M)

34% less call options, than puts

Call options by funds: $29.5M | Put options by funds: $44.9M

38% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 56

Holders
132
Holders Change
-22
Holders Change %
-14.29%
% of All Funds
3.68%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
35
Increased
54
Reduced
28
Closed
56
Calls
$29.5M
Puts
$44.9M
Net Calls
-$15.4M
Net Calls Change
+$15.4M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$131M
2
BB
BB Biotech
Switzerland
+$37.5M
3
BIT
BlackRock Institutional Trust
California
+$29M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.7M
5
State Street
State Street
Massachusetts
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$16.3M
2
Citadel Advisors
Citadel Advisors
Florida
-$15.6M
3
RCM
RA Capital Management
Massachusetts
-$14.9M
4
JP Morgan Chase
JP Morgan Chase
New York
-$13.2M
5
DM
Deerfield Management
New York
-$9.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
26
Marsico Capital Management
Colorado
$5.45M +$1.25M +28,545 +27%
Zurich Cantonal Bank
27
Zurich Cantonal Bank
Switzerland
$5.02M +$5.03M +114,722 +1,328%
Northern Trust
28
Northern Trust
Illinois
$4.76M +$2.82M +64,371 +122%
UBS AM
29
UBS AM
Illinois
$4.46M +$1.98M +45,117 +70%
Ameriprise
30
Ameriprise
Minnesota
$4.3M -$122K -2,787 -3%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$4.2M +$2.41M +54,898 +114%
T. Rowe Price Associates
32
T. Rowe Price Associates
Maryland
$3.98M -$12.9K -294 -0.3%
Citigroup
33
Citigroup
New York
$3.75M +$1.93M +44,077 +92%
HSBC Holdings
34
HSBC Holdings
United Kingdom
$3.71M +$117K +2,666 +3%
US Bancorp
35
US Bancorp
Minnesota
$3.54M +$3.33M +76,000 +685%
UBS Group
36
UBS Group
Switzerland
$3.41M +$3.23M +73,668 +724%
BBA
37
Baker Bros. Advisors
New York
$3.25M – – –
TAM
38
Tocqueville Asset Management
New York
$3.19M +$535K +12,195 +18%
TCIM
39
TIAA CREF Investment Management
New York
$3.01M +$677K +15,432 +26%
PHS
40
PFM Health Sciences
California
$3M -$1.99M -45,323 -38%
TI
41
Turner Investments
Pennsylvania
$2.83M +$3.06M +69,680 New
SCM
42
Suffolk Capital Management
New York
$2.82M +$3.04M +69,298 New
SC
43
Sculptor Capital
New York
$2.38M +$2.57M +58,500 New
RIM
44
RS Investment Management
California
$2.35M +$829K +18,900 +49%
PA
45
Profund Advisors
Maryland
$2.02M +$2.18M +49,756 New
MSU
46
Mizuho Securities USA
New York
$2.02M +$2.18M +49,600 New
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$1.64M -$8.73K -199 -0.5%
PIM
48
Platinum Investment Management
Australia
$1.63M – – –
TA
49
Teachers Advisors
New York
$1.61M +$507K +11,552 +41%
CGI
50
CI Global Investments
California
$1.57M +$1.69M +38,617 New
1
2
3 4 5

JUNO Hedge Fund Activity: Q3 2015 in Review

132 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q3 2015, worth a combined $2.17B — down 14% from $2.54B a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of JUNO and 35 opened new positions — a net loss of 21 holders — while 28 trimmed existing stakes and 54 added.

The largest buyer was Vanguard Group, adding an estimated $131M. The largest seller was Lord, Abbett & Co, cutting an estimated $16.3M.

  • 132 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q3 2015, down from 154 in Q2 2015.
  • Funds reported $2.17B of Juno Therapeutics, Inc. stock for Q3 2015, down 14% quarter-over-quarter.
  • 35 funds opened new Juno Therapeutics, Inc. positions in Q3 2015 and 56 closed out, a net change of -21 holders.
  • The largest Juno Therapeutics, Inc. buyer in Q3 2015 was Vanguard Group, an estimated $131M added.
  • The largest Juno Therapeutics, Inc. seller in Q3 2015 was Lord, Abbett & Co, an estimated $16.3M sold.

Based on aggregated 13F filings for Q3 2015.